iShares Biotechnology ETF
837 hedge funds and large institutions have $3.99B invested in iShares Biotechnology ETF in 2025 Q1 according to their latest regulatory filings, with 49 funds opening new positions, 198 increasing their positions, 361 reducing their positions, and 81 closing their positions.
2.19% less ownership
Funds ownership: 71.02% → 68.83% (-2.2%)
5% less funds holding
Funds holding: 880 → 837 (-43)
27% less funds holding in top 10
Funds holding in top 10: 11 → 8 (-3)
40% less first-time investments, than exits
New positions opened: 49 | Existing positions closed: 81
45% less repeat investments, than reductions
Existing positions increased: 198 | Existing positions reduced: 361
54% less call options, than puts
Call options by funds: $293M | Put options by funds: $630M
55% less capital inflows, than outflows
Capital inflows: $381M | Capital outflows: $850M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citigroup
New York
|
+$183M |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$42.5M |
| 3 |
Wells Fargo
San Francisco,
California
|
+$27.7M |
| 4 |
JP Morgan Chase
New York
|
+$22.2M |
| 5 |
Squarepoint
New York
|
+$9.04M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
-$230M |
| 2 |
Morgan Stanley
New York
|
-$91.4M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$70.8M |
| 4 |
BNP Paribas Financial Markets
Paris,
France
|
-$61M |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$59.9M |
IBB Hedge Fund Activity: Q1 2025 in Review
837 of the 7,484 institutional investors tracked by Wall St. Rank reported a position in iShares Biotechnology ETF (IBB) for Q1 2025, worth a combined $3.99B — down 13% from $4.59B a quarter earlier.
Sellers outnumbered buyers: 81 funds closed out of IBB and 49 opened new positions — a net loss of 32 holders — while 361 trimmed existing stakes and 198 added.
The largest buyer was Citigroup, adding an estimated $183M. The largest seller was Jane Street, cutting an estimated $230M.
- 837 institutional investors held iShares Biotechnology ETF (IBB) as of Q1 2025, down from 880 in Q4 2024.
- Funds reported $3.99B of iShares Biotechnology ETF stock for Q1 2025, down 13% quarter-over-quarter.
- 49 funds opened new iShares Biotechnology ETF positions in Q1 2025 and 81 closed out, a net change of -32 holders.
- The largest iShares Biotechnology ETF buyer in Q1 2025 was Citigroup, an estimated $183M added.
- The largest iShares Biotechnology ETF seller in Q1 2025 was Jane Street, an estimated $230M sold.
Based on aggregated 13F filings for Q1 2025.